Advertisement
| dostarlimab fda approval history: Rectal Cancer Treatment M.W. Büchler, R. J. Heald, B. Ulrich, J. Weitz, 2005-10-11 Rectal cancer is one of the most prevalent cancers world-wide. It is also a paradigm for multimodal management, as the combination of surgery, chemotherapy and radiotherapy is often necessary to achieve the optimal outcome. Recently, international experts met in Heidelberg, Germany to discuss the latest developments in the management of rectal cancer, including the anatomic and pathologic basis, staging tools, surgical concepts including fast-track surgery and laparoscopic resection, functional outcome after surgery and the role of radio- and chemotherapy. This monograph summarizes this meeting and gives an extensive overview of the current concepts in management of rectal cancer. |
| dostarlimab fda approval history: Management of Endometrial Cancer Mansoor R. Mirza, 2019-08-26 This practical reference book provides up-to-date, evidence-based multidisciplinary guidelines on the epidemiology, biology, diagnosis, and treatment of endometrial cancer. Individual chapters focus on topics such as hormonal interactions, cancer prevention, genetic classification and its clinical applications. Recent advances in diagnostic methods are described. The treatment-oriented chapters include coverage of the roles of lymphadenectomy and sentinel node dissection, surgical complications, radiation techniques, and chemotherapy in early-stage disease. Treatment options in advanced disease, including hormonal therapy and targeted therapy, are considered separately, as is the management of rare tumor types. The authors are international key opinion leaders. Summaries of the ESMO/ESGO/ESTRO guidelines on management are included. Each clinical chapter ends with a summary of recommendations with the level of evidence. |
| dostarlimab fda approval history: Upper Tract Urothelial Carcinoma Shahrokh F. Shariat, Evanguelos Xylinas, 2014-09-13 Upper Tract Urothelial Carcinoma represents the first book of its kind to be dedicated solely to UTUC. It's aim is to improve understanding and eventually care of a disease that is greatly understudied and underappreciated, yet commonly dealt with by many medical and urologic oncologists. The volume features new data regarding genetic susceptibility, gene expression studies and causative factors; contemporary concepts and controversies regarding diagnosis and staging of UTUC; prediction tools and their value in treatment decisions within each disease stage and patient selection and treatment options such as endoscopic management, distal ureterectomy, radical nephroureterectomy and chemotherapy. Up-to-date information regarding boundaries of surgical resection, indication and extent of lymphadenectomy is covered as well as the role of perioperative/neoadjuvant chemotherapy in patients with high-risk UTUC. Upper Tract Urothelial Carcinoma will be of great value to all Urologists, Medical Oncologists and fellows in Urologic Oncology as well as upper level residents in training in Urology and Medical Oncology. |
| dostarlimab fda approval history: Immunologic Concepts in Transfusion Medicine Robert W Maitta, 2019-08-27 Immunological Concepts in Transfusion Medicine provides a thorough discussion of the immune aspects of blood component transfusion, with in-depth information on the intricacies of immune responses to blood components and the immune processes that may be initiated in response to blood exposure. Written to increase knowledge and awareness of immune challenges such as alloimmunization and transfusion-related acute lung injury, this title bridges current basic scientific discoveries and the potential effects seen in blood recipients. - Complies the knowledge and expertise of Dr. Robert Maitta, an expert in immune responses and antibody function/structure studies. - Helps clinicians in the daily practice of caring for patients in need of transfusion support, as well as physicians in training when considering utilizing blood transfusions in a limited scope or in the setting of massive transfusion. - Includes an immunology primer as an introduction to in-depth chapters covering allergic immune reactions to blood components, transfusion-related immunomodulation, fetal and neonatal alloimmune thrombocytopenia and neonatal neuthropenia, complications of haploidentical and mismatched HSC transplantation, chimeric antibody receptor therapies, and much more. - Consolidates today's available information on this timely topic into a single, convenient resource. |
| dostarlimab fda approval history: Precision Medicine in Oncology Bulent Aydogan, James A. Radosevich, 2020-11-02 A FRESH EXAMINATION OF PRECISION MEDICINE'S INCREASINGLY PROMINENT ROLE IN THE FIELD OF ONCOLOGY Precision medicine takes into account each patient's specific characteristics and requirements to arrive at treatment plans that are optimized towards the best possible outcome. As the field of oncology continues to advance, this tailored approach is becoming more and more prevalent, channelling data on genomics, proteomics, metabolomics and other areas into new and innovative methods of practice. Precision Medicine in Oncology draws together the essential research driving the field forward, providing oncology clinicians and trainees alike with an illuminating overview of the technology and thinking behind the breakthroughs currently being made. Topics covered include: Biologically-guided radiation therapy Informatics for precision medicine Molecular imaging Biomarkers for treatment assessment Big data Nanoplatforms Casting a spotlight on this emerging knowledge base and its impact upon the management of tumors, Precision Medicine in Oncology opens up new possibilities and ways of working not only for oncologists, but also for molecular biologists, radiologists, medical geneticists, and others. |
| dostarlimab fda approval history: Translational Urology Anthony Atala, Ali Arab, Mohummad Minhaj Siddiqui, Adam E.M. Eltorai, 2024-10-09 Translational Urology covers the principles of evidence-based medicine and applies these principles to the design of translational investigations. The reader will come to fully understand important concepts, including case-control study, prospective cohort study, randomized trial, and reliability study. Medical researchers will benefit from greater confidence in their ability to initiate and execute their own investigations, avoid common pitfalls in urology, and know what is needed for successful collaboration. Further, this title is an indispensable tool in grant writing and funding efforts.This practical, straightforward approach helps the aspiring investigator navigate challenging considerations in study design and implementation. The book provides valuable discussions of the critical appraisal of published studies in urology, allowing the reader to learn how to evaluate the quality of such studies with respect to measuring outcomes and to make effective use of all types of evidence in patient care. - Focuses on the principles of evidence-based medicine and applies these principles to the design of translational investigations within the field of urology - Provides a practical, straightforward approach that helps investigators navigate challenging considerations in study design and implementation - Details discussions of the critical appraisal of published studies in urology, supporting evaluation with respect to measuring outcomes and making effective use of all types of evidence in patient care |
| dostarlimab fda approval history: Practical Medical Oncology Textbook Antonio Russo, Marc Peeters, Lorena Incorvaia, Christian Rolfo, 2021-10-06 This textbook combines essential information on clinical cancer medicine with a guide to the latest advances in molecular oncology and tumor biology. Providing a systematic overview of all types of solid tumors, including epidemiology and cancer prevention, genetic aspects of hereditary cancers, differential diagnosis, typical signs and symptoms, diagnostic strategies and staging, and treatment modalities, it also discusses new and innovative cancer treatments, particularly targeted therapy and immunotherapy. Expert commentaries at the end of each chapter highlight key points, offer insights, suggest further reading and discuss clinical application using case descriptions. This textbook is an invaluable, practice-oriented tool for medical students just beginning their clinical oncology studies, as well as for medical oncology residents and young professionals. |
| dostarlimab fda approval history: Growth Hormone Deficiency in Adults Jens O. L. Jørgensen, Jens Sandahl Christiansen, 2005-01-01 It has been known for over 40 years that GH-deficient-children benefit from replacement with the hormone. But GH, essential for longitudinal growth, also plays a role after completion of final height. With the introduction of biosynthetic human GH 20 years ago, the use of GH was no longer restricted to severe growth retardation in hypopituitary children. This book will take the reader behind the myths of GH and into the real world of clinical endocrinology. The contributions stem from recognized clinicians and scientists who have been working in the field for decades. The contents encompass traditional end points of GH therapy such as body composition, bone biology and physical performance. Attention is also devoted to diagnostic aspects and side effects. Additional features range from clinical epidemiology to quality of life, and novel areas such as the impact of traumatic brain injury on pituitary function are also covered. The present volume of Frontiers of Hormone Research is essential reading for health care professionals interested in clinical endocrinology and GH. |
| dostarlimab fda approval history: Oncoimmunology Laurence Zitvogel, Guido Kroemer, 2017-12-13 In this book, leading experts in cancer immunotherapy join forces to provide a comprehensive guide that sets out the main principles of oncoimmunology and examines the latest advances and their implications for clinical practice, focusing in particular on drugs with FDA/EMA approvals and breakthrough status. The aim is to deliver a landmark educational tool that will serve as the definitive reference for MD and PhD students while also meeting the needs of established researchers and healthcare professionals. Immunotherapy-based approaches are now inducing long-lasting clinical responses across multiple histological types of neoplasia, in previously difficult-to-treat metastatic cancers. The future challenges for oncologists are to understand and exploit the cellular and molecular components of complex immune networks, to optimize combinatorial regimens, to avoid immune-related side effects, and to plan immunomonitoring studies for biomarker discovery. The editors hope that this book will guide future and established health professionals toward the effective application of cancer immunology and immunotherapy and contribute significantly to further progress in the field. |
| dostarlimab fda approval history: Advancing Healthcare Through Personalized Medicine Priya Hays, 2021-09-27 This book provides a unique perspective on the biomedical and societal implications of personalized medicine and how it helps to mitigate the healthcare crisis and rein in ever-growing expenditure. It introduces the reader to the underlying concepts at the heart of personalized medicine. An innovative second edition, this book functions as an update to the successful first edition to include new, state-of-the-art information and advancements in the fast-paced field of personalized medicine. Chapters examine pharmacogenomics, targeted therapies, individualized diagnosis and treatment, and cancer immunotherapies. The book also features an essential discussion on how the advent of genomic technologies gives clinicians the capability to predict and diagnose disease more efficiently and offers a detailed up-to-date compilation of clinical trials in cancer leading to breakthrough therapies. The book also addresses the impact of Big Data on personalized medicine and the newfound applications of digital health and artificial intelligence. A work that advocates for a patient-centered approach, Advancing Healthcare Through Personalized Medicine, Second Edition is an invaluable text for clinicians, healthcare providers, and patients. |
| dostarlimab fda approval history: Overcoming Ovarian Cancer Chemoresistance Goli Samimi, Christina Annunziata, 2020-11-24 Overcoming Ovarian Cancer Chemoresistance presents non-overlapping review chapters that discuss the state of the field in overcoming chemoresistance of ovarian cancer and treatment options before and following recurrence, considering the genetic makeup of the ovarian cancer patient and her tumor. With the uptake of both germline and somatic gene testing, clinicians can obtain a more comprehensive understanding of ovarian tumors and this book provides information to link the genetic makeup of a tumor (or patient) with the best available treatment. The book discusses topics such as strategies to fight chemo-resistance in ovarian cancer, circulating DNA as a monitor of response, BRCA mutations, ovarian cancer stem cells, immunotherapy and vaccines. Additionally, it brings a list of promising agents at clinical and pre-clinical stage that will impact the treatment in the near future. This book is a valuable source for cancer researchers, oncologists and several members of biomedical field who need to understand how to battle chemoresistance in ovarian cancer. Provides a comprehensive view of both biological and genetic determinants of resistance, as well as technical approaches to monitor response Discusses genetic reversions as a unique alteration and a new field of study Includes a chapter on upcoming and promising agents that are in the pre-clinical and early clinical space, to set the stage for future directions in the field |
| dostarlimab fda approval history: Multiple Myeloma Morie A. Gertz, S. Vincent Rajkumar, 2013-10-01 This is a comprehensive, state-of-the-art guide to the diagnosis, treatment, and biology of multiple myeloma and related plasma disorders. Edited and written by a multidisciplinary group of recognized authorities from the Mayo Clinic, it presents clear guidelines on diagnosis and therapy and covers all aspects of multiple myeloma, from molecular classification and diagnosis, to risk stratification and therapy. Closely related plasma cell disorders such as solitary plasmacytoma, Waldenstrom macroglobulinemia, and light chain amyloidosis are discussed in detail as well. The book addresses often overlooked topics, including the role of radiation therapy, vertebral augmentation, and supportive care. Our understanding of this group of disorders is developing at an unprecedented rate, and Multiple Myeloma meets the need among oncologists and hematologists for a clear, timely, and authoritative resource on their biology, diagnosis, and treatment. |
| dostarlimab fda approval history: Monoclonal Antibody Production National Research Council, Institute for Laboratory Animal Research, Committee on Methods of Producing Monoclonal Antibodies, 1999-05-06 The American Anti-Vivisection Society (AAVS) petitioned the National Institutes of Health (NIH) on April 23, 1997, to prohibit the use of animals in the production of mAb. On September 18, 1997, NIH declined to prohibit the use of mice in mAb production, stating that the ascites method of mAb production is scientifically appropriate for some research projects and cannot be replaced. On March 26, 1998, AAVS submitted a second petition, stating that NIH failed to provide valid scientific reasons for not supporting a proposed ban. The office of the NIH director asked the National Research Council to conduct a study of methods of producing mAb. In response to that request, the Research Council appointed the Committee on Methods of Producing Monoclonal Antibodies, to act on behalf of the Institute for Laboratory Animal Research of the Commission on Life Sciences, to conduct the study. The 11 expert members of the committee had extensive experience in biomedical research, laboratory animal medicine, animal welfare, pain research, and patient advocacy (Appendix B). The committee was asked to determine whether there was a scientific necessity for the mouse ascites method; if so, whether the method caused pain or distress; and, if so, what could be done to minimize the pain or distress. The committee was also asked to comment on available in vitro methods; to suggest what acceptable scientific rationale, if any, there was for using the mouse ascites method; and to identify regulatory requirements for the continued use of the mouse ascites method. The committee held an open data-gathering meeting during which its members summarized data bearing on those questions. A 1-day workshop (Appendix A) was attended by 34 participants, 14 of whom made formal presentations. A second meeting was held to finalize the report. The present report was written on the basis of information in the literature and information presented at the meeting and the workshop. |
| dostarlimab fda approval history: Plotkin's Vaccines,E-Book Walter A. Orenstein, Paul A. Offit, Kathryn M. Edwards, Stanley A. Plotkin, 2022-12-21 From the latest vaccination evidence, recommendations, and protocols . . . to new vaccine development and the use of vaccines in reducing disease, Plotkin's Vaccines, 8th Edition, covers every aspect of vaccination. Now completely revised and updated from cover to cover, this award-winning text continues to provide reliable information from global authorities, offering a complete understanding of each disease, as well as the latest knowledge of both existing vaccines and those currently in research and development. Described by Bill Gates as an indispensable guide to the enhancement of the well-being of our world, Plotkin's Vaccines is a must-have reference for current, authoritative information in this fast-moving field. - Contains all-new chapters on COVID-19, vaccine hesitancy, and non-specific effects of vaccines, as well as significantly revised content on new vaccine technologies such as mRNA vaccines, emerging vaccines, and technologies to improve immunization. - Presents exciting new data on evolution of adjuvants across the centuries, dengue vaccines, human papillomavirus vaccines, respiratory syncytial virus vaccines, tuberculosis vaccines, and zoster vaccines. - Provides up-to-date, authoritative information on vaccine production, available preparations, efficacy and safety, and recommendations for vaccine use, with rationales and data on the impact of vaccination programs on morbidity and mortality. - Provides complete coverage of each disease, including clinical characteristics, microbiology, pathogenesis, diagnosis, and treatment, as well as epidemiology and public health and regulatory issues. - Keeps you up to date with information on each vaccine, including its stability, immunogenicity, efficacy, duration of immunity, adverse events, indications, contraindications, precautions, administration with other vaccines, and disease-control strategies. - Covers vaccine-preventable diseases, vaccine science, and licensed vaccine products, as well as product technologies and global regulatory and public health issues. - Analyzes the cost-benefit and cost-effectiveness of different vaccine options. - Helps you clearly visualize concepts and objective data through an abundance of tables and figures. - Enhanced eBook version included with purchase. Your enhanced eBook allows you to access all of the text, figures, and references from the book on a variety of devices. |
| dostarlimab fda approval history: Ovarian Cancer Immunotherapy Samir A. Farghaly, 2018-08-31 Ovarian Cancer Immunotherapy provides a broad overview of several aspects of basic sciences, and clinical and therapeutic aspects of immunotherapy for ovarian cancer, as well as state-of-the-art information on molecular genetics and biology. Chapters are written by a team of expert contributors from around the world and explore topics such as antibody therapeutics for ovarian carcinoma, emerging serum biomarkers, ovarian cancer immunity, adoptive cell immunotherapy, the biology of dendritic cells, the role of growth factors, and more. Readers will also gain a better understanding of the molecular and cellular events that underlie ovarian cancer immunology. This book is an ideal resource for clinicians, basic medical scientists, graduate basic medical science students, and medical students caring for patients with ovarian cancer, including attending surgeons and physicians, and clinical fellows and residents in the disciplines of gynecologic oncology, medical oncology, and surgical oncology. |
| dostarlimab fda approval history: Lipid Nanocarriers for Drug Targeting Alexandru Mihai Grumezescu, 2018-04-16 Lipid Nanocarriers for Drug Targeting presents recent advances in the area of lipid nanocarriers. The book focuses on cationic lipid nanocarriers, solid lipid nanocarriers, liposomes, thermosensitive vesicles, and cubosomes, with applications in phototherapy, cosmetic and others. As the first book related to lipid nanocarriers and their direct implication in pharmaceutical nanotechnology, this important reference resource is ideal for biomaterials scientists and those working in the medical and pharmaceutical industries that want to learn more on how lipids can be used to create more effective drug delivery systems. - Highlights the most commonly used types of lipid nanocarriers and explains how they are applied in pharmacy - Shows how lipid nanocarriers are used in different types of treatment, including oral medicine, skin repair and cancer treatment - Assesses the pros and cons of using different lipid nanocarriers for different therapies |
| dostarlimab fda approval history: Cancer of the Female Reproductive Organs National Cancer Institute (U.S.), 1959 |
| dostarlimab fda approval history: In the Nation's Compelling Interest Institute of Medicine, Board on Health Sciences Policy, Committee on Institutional and Policy-Level Strategies for Increasing the Diversity of the U.S. Health Care Workforce, 2004-06-29 The United States is rapidly transforming into one of the most racially and ethnically diverse nations in the world. Groups commonly referred to as minorities-including Asian Americans, Pacific Islanders, African Americans, Hispanics, American Indians, and Alaska Natives-are the fastest growing segments of the population and emerging as the nation's majority. Despite the rapid growth of racial and ethnic minority groups, their representation among the nation's health professionals has grown only modestly in the past 25 years. This alarming disparity has prompted the recent creation of initiatives to increase diversity in health professions. In the Nation's Compelling Interest considers the benefits of greater racial and ethnic diversity, and identifies institutional and policy-level mechanisms to garner broad support among health professions leaders, community members, and other key stakeholders to implement these strategies. Assessing the potential benefits of greater racial and ethnic diversity among health professionals will improve the access to and quality of healthcare for all Americans. |
| dostarlimab fda approval history: FDA Approval of New Drugs United States. Food and Drug Administration, 1971 |
| dostarlimab fda approval history: Reducing Adverse Effects of Cancer Immunotherapy Daniele Maria-Ferreira, Cleber Machado-Souza, Elizabeth S. Fernandes, 2024-02-13 Chemotherapy and/or radiotherapy remain the main treatment options for most cancers. However, cancer treatment is associated with numerous adverse effects, including fatigue, stress, hair loss, pain, nausea, vomiting, anemia, altered immune system, oral and intestinal mucositis, which significantly affect patients' quality of life. In addition, the adverse effects may be associated with additional costs, morbidity, and mortality that affect various aspects of the patient's life, including physical health and emotional state. The management and reduction of adverse effects are extremely important and complex and are primarily aimed at providing comfort to the patient during chemotherapy treatment. In addition, it is important to note that in some cases, the severity of side effects associated with cancer treatment may result in the need to reduce the dose, which in turn may be associated with a reduction in the therapeutic efficacy. In view of this, the identification of new options aimed at alleviating the side effects and increasing the tolerability of chemotherapy is necessary to ensure the quality of life of cancer patients. |
| dostarlimab fda approval history: Principles and Practice of Gynecologic Oncology Richard R. Barakat, Maurie Markman, Marcus Randall, 2009 Providing comprehensive coverage of the biology of gynecologic cancer, the therapeutic modalities available, and the diagnosis and treatment of site-specific malignancies, this edition has 30 percent new contributing authors and new material. A companion Web site offers a fully searchable text. |
| dostarlimab fda approval history: Pocket Oncology Alexander Drilon, Michael Postow, 2014 Pocket Oncology, developed and edited by oncologists at Memorial Sloan-Kettering Cancer Center, is a simple, yet comprehensive, review of basic principles of cancer management. Prepared in the style and format of books in the popular Pocket Notebook series, Pocket Oncology is intended as a quick reference presented in easy to read bulleted text, and using diagrams and charts where appropriate. Each oncologic disease is presented on two facing pages that review initial clinical presentation, pathophysiology, staging, current standard of care treatments, and active areas of current research. Edited by Alexander Drilon and Michael Postow, the content of the book has been written by medical oncology fellows and each disease entity has been authoritatively reviewed by an oncologist with specific expertise in each subspecialty of oncology. Features: -simple, comprehensive, review of basic principles of oncology in easy to read bulleted text, using diagrams and charts where appropriate. -its small size makes it easy to carry the pocket of a lab coat for quick reference to information while in the hospital or oncology clinic. -perfect for medical students, residents, fellows, physician assistants, and nurses who perform daily oncologic care. |
| dostarlimab fda approval history: Antibody Drug Discovery Clive R. Wood, 2012 Antibody-based therapeutics are a central driver of the success of biopharmaceuticals. The discovery technology of this field is isolated to a limited number of centers of excellence in industry and academia. The objective of this volume is to provide a series of guides to those evaluating and preparing to enter particular areas within the field. Each chapter is written with a historical perspective that sets into context the significance of the key developments, and with the provision of “points to consider” for the reader as a value-added feature of the volume. All contributors are experts in their fields and have played pivotal roles in the creation of the technology. |
| dostarlimab fda approval history: British Pharmaceutical Codex , 1907 |
| dostarlimab fda approval history: Female Genital Tumours: Who Classification of Tumours W. H. O. Classification WHO Classification of Tumours Editorial Board, Who Classification of Tumours Editorial, 2020-09-30 ****When not purchasing directly from the official sales agents of the WHO, especially at online bookshops, please note that there have been issues with counterfeited copies. Buy only from known sellers and if there are quality issues, please contact the seller for a refund.***** Female Genital Tumours is the fourth volume in the 5th edition of the WHO series on the classification of human tumours. This series (also known as the WHO Blue Books) is regarded as the gold standard for the diagnosis of tumours and comprises a unique synthesis of histopathological diagnosis with digital and molecular pathology. These authoritative and concise reference books provide indispensable international standards for anyone involved in the care of patients with cancer or in cancer research, underpinning individual patient treatment as well as research into all aspects of cancer causation, prevention, therapy, and education. What's new in this edition? The 5th edition, guided by the WHO Classification of Tumours Editorial Board, will establish a single coherent cancer classification presented across a collection of individual volumes organized on the basis of anatomical site (digestive system, breast, soft tissue and bone, etc.) and structured in a systematic manner, with each tumour type listed within a taxonomic classification: site, category, family (class), type, and subtype. In each volume, the entities are now listed from benign to malignant and are described under an updated set of headings, including histopathology, diagnostic molecular pathology, staging, and easy-to-read essential and desirable diagnostic criteria. Who should read this book? - Pathologists - Oncologists - Cancer researchers - Surgeons - Epidemiologists - Cancer registrars This volume - Prepared by 191 authors and editors - Contributors from around the world - More than 850 high-quality images - More than 3100 references |
| dostarlimab fda approval history: How We Do Harm Otis Webb Brawley, MD, Paul Goldberg, 2012-01-31 A startling and important exposé on the state of medicine, research, and healthcare today by the Chief Medical and Scientific Officer of the American Cancer Society How We Do Harm exposes the underbelly of healthcare today—the overtreatment of the rich, the under treatment of the poor, the financial conflicts of interest that determine the care that physicians' provide, insurance companies that don't demand the best (or even the least expensive) care, and pharmaceutical companies concerned with selling drugs, regardless of whether they improve health or do harm. Dr. Otis Brawley is the chief medical and scientific officer of The American Cancer Society, an oncologist with a dazzling clinical, research, and policy career. How We Do Harm pulls back the curtain on how medicine is really practiced in America. Brawley tells of doctors who select treatment based on payment they will receive, rather than on demonstrated scientific results; hospitals and pharmaceutical companies that seek out patients to treat even if they are not actually ill (but as long as their insurance will pay); a public primed to swallow the latest pill, no matter the cost; and rising healthcare costs for unnecessary—and often unproven—treatments that we all pay for. Brawley calls for rational healthcare, healthcare drawn from results-based, scientifically justifiable treatments, and not just the peddling of hot new drugs. Brawley's personal history – from a childhood in the gang-ridden streets of black Detroit, to the green hallways of Grady Memorial Hospital, the largest public hospital in the U.S., to the boardrooms of The American Cancer Society—results in a passionate view of medicine and the politics of illness in America - and a deep understanding of healthcare today. How We Do Harm is his well-reasoned manifesto for change. |
| dostarlimab fda approval history: STD Fact Sheet , 1978 |
| dostarlimab fda approval history: Immunotherapy in Resistant Cancer: From the Lab Bench Work to Its Clinical Perspectives Jorge Morales-Montor, Mariana Segovia-Mendoza, 2020-10-02 Immunotherapy in Resistant Cancer: From the Lab Bench Work to Its Clinical Perspectives provides high level knowledge on detailed mechanisms of actions and biological interactions of different immune drugs, with an aim of offering researchers and clinicians cutting-edge therapies to overcome drug resistance. The book explains the latest immunotherapies for different types of cancer, helping users carry out research projects or create alternatives for drug development in the pharmaceutical industry. Topics discussed include the relationship between immunotherapy and macrophages, immune checkpoints in different types of cancer, immune cocktails in solid tumors, and immune-phenotyping. Additionally, the book presents basic and clinical data on immunoresistance and glycosylation. This book is a valuable source for cancer researchers, medical doctors, clinicians and members of the biomedical field who must understand certain mechanisms to fight cancer that is resistant to immunotherapy. |
| dostarlimab fda approval history: Carbon-Ion Radiotherapy Hirohiko Tsujii, Tadashi Kamada, Toshiyuki Shirai, Koji Noda, Hiroshi Tsuji, Kumiko Karasawa, 2013-12-25 This book serves as a practical guide for the use of carbon ions in cancer radiotherapy. On the basis of clinical experience with more than 7,000 patients with various types of tumors treated over a period of nearly 20 years at the National Institute of Radiological Sciences, step-by-step procedures and technological development of this modality are highlighted. The book is divided into two sections, the first covering the underlying principles of physics and biology, and the second section is a systematic review by tumor site, concentrating on the role of therapeutic techniques and the pitfalls in treatment planning. Readers will learn of the superior outcomes obtained with carbon-ion therapy for various types of tumors in terms of local control and toxicities. It is essential to understand that the carbon-ion beam is like a two-edged sword: unless it is used properly, it can increase the risk of severe injury to critical organs. In early series of dose-escalation studies, some patients experienced serious adverse effects such as skin ulcers, pneumonitis, intestinal ulcers, and bone necrosis, for which salvage surgery or hospitalization was required. To preclude such detrimental results, the adequacy of therapeutic techniques and dose fractionations was carefully examined in each case. In this way, significant improvements in treatment results have been achieved and major toxicities are no longer observed. With that knowledge, experts in relevant fields expand upon techniques for treatment delivery at each anatomical site, covering indications and optimal treatment planning. With its practical focus, this book will benefit radiation oncologists, medical physicists, medical dosimetrists, radiation therapists, and senior nurses whose work involves radiation therapy, as well as medical oncologists and others who are interested in radiation therapy. |
| dostarlimab fda approval history: Cell-wide Metabolic Alterations Associated with Malignancy , 2014-06-16 This new volume of Methods in Enzymology continues the legacy of this premier serial with quality chapters authored by leaders in the field. This volume covers research methods providing a a theoretical overview on metabolic alterations of cancer cells and a series of protocols that can be employed to study oncometabolism, in vitro, ex vivo and in vivo. Malignant cells exhibit metabolic changes when compared to their normal counterparts, owing to both genetic and epigenetic alterations. Although such a metabolic rewiring has recently been indicated as yet another general hallmark of cancer, accumulating evidence suggests that the metabolic alterations of each neoplasm rather represent a molecular signature that intimately accompanies, and hence cannot be severed from, all facets of malignant transformation. |
| dostarlimab fda approval history: Molecular Predictive Pathology in Gynecologic Malignancies Umberto Malapelle, Pierluigi Giampaolino, Stefano Uccella, Sabrina Chiara Cecere, 2023-11-13 |
| dostarlimab fda approval history: Negative Co-Receptors and Ligands Rafi Ahmed, Tasuku Honjo, 2011-04-11 Adaptive immune responses serve as a key defense mechanism for the control of infections in vertebrates. Immune responses must be of sufficient strength to contain invading pathogens, antigen specific responses require regulatory mechanisms to ensure termination or downmodulation to avoid excessive damage to the host tissue. For both branches of the adaptive immune system, regulatory molecules i.e. coreceptors and ligands have been identified that control the signaling cascades initiated by engagement of the T cell and B cell antigen receptors. This book describes biological functions as well as molecular mechanisms of these molecules. |
| dostarlimab fda approval history: Brachytherapy Paolo Montemaggi, Mark Trombetta, Luther W. Brady, 2016-04-21 This volume is the first truly international text to take the practitioner from the history, the physical basis, and the rationale of brachytherapy through to the techniques, the results, and the management of complications. It is also the first truly comprehensive and complete textbook of brachytherapy. The chapters on the physics of brachytherapy and the technical planning of internal and surface radiotherapy are designed to enhance the practitioner’s knowledge base and capabilities in this demanding specialty field. Disease site-specific chapters cover a wide range of applications, including ocular tumors, soft tissue sarcomas, cancers of the head and neck, skin, breast, lung, esophagus, and prostate, and gynecologic and anorectal malignancies. Each chapter incorporates the American and European guidelines and the text has been written from both perspectives by many of the most noted global experts in the field. A concluding chapter is devoted to brachytherapy quality assurance. |
| dostarlimab fda approval history: Video Atlas Leslie H. Blumgart, 2010-09-22 Dr. Leslie H Blumgart has developed an extensive library of high-quality, narrated, and captioned videos that present history, radiologic evidence, and operative procedures-from major and minor resectional procedures to biliary and pancreatic anastomotic techniques. Dr. Carlos U. Corvera has worked with Dr. Blumgart to contribute laparoscopic alternatives to these innovative and landmark surgeries. On DVD, and in print, this multimedia resource provides detailed, practical instruction on this challenging area of surgery. Master difficult, complex, and lesser-known surgeries through more than 10 hours of high-quality procedural videos narrated by Dr. Leslie H. Blumgart-a pioneer in the field. See how an expert handles difficult cases from clear illustrations and step-by-step discussions of procedures, including Dr. Blumgart's personal techniques. Get coverage of major and minor resectional procedures, biliary tract and pancreatic resection, biliary and pancreatic anastomotic techniques, and more-including newly pioneered minimally invasive procedures from Dr. Carlos U. Corvera. |
| dostarlimab fda approval history: Imaging in Hepatobiliary and Pancreatic Disease Dirk J. Van Leeuwen, Joe Ariyama, Jacques W. A. J. Reeders, 2000 A new, highly practical guide to the selection of appropriate imaging modalities for the most common clinical problems. Covers conditions such as gallstones, acute and chronic pancreatitis, space-occupying lesions, portal hypertension, and more. Emphasizes the strengths and weaknesses of specific techniques, potential risks and side effects, comparative costs, and cost effectiveness. |
| dostarlimab fda approval history: Translating Gene Therapy to the Clinic Jeffrey Laurence, Michael Franklin, 2014-11-14 Translating Gene Therapy to the Clinic, edited by Dr. Jeffrey Laurence and Michael Franklin, follows the recent, much-lauded special issue of Translational Research in emphasizing clinical milestones and critical barriers to further progress in the clinic. This comprehensive text provides a background for understanding the techniques involved in human gene therapy trials, and expands upon the disease-specific situations in which these new approaches currently have the greatest therapeutic application or potential, and those areas most in need of future research. It emphasizes methods, tools, and experimental approaches used by leaders in the field of translational gene therapy. The book promotes cross-disciplinary communication between the sub-specialties of medicine, and remains unified in theme. - Presents impactful and widely supported research across the spectrum of science, method, implementation and clinical application - Offers disease-based coverage from expert clinician-scientists, covering everything from arthritis to congestive heart failure, as it details specific progress and barriers for current translational use - Provides key background information from immune response through genome engineering and gene transfer, relevant information for practicing clinicians contemplating enrolling patients in gene therapy trials |
| dostarlimab fda approval history: Glycan-Based Cellular Communication Peng George Wang, 2020 |
| dostarlimab fda approval history: The Cure for All Cancers Hulda Regehr Clark, 2002-08 As new research findings show that there is a single cause for all cancers this book provides exact instruction over 100 case histories of the persons cured. |
| dostarlimab fda approval history: World Cancer Report 2014 Bernard W. Stewart, Christopher P. Wild, 2014 World Cancer Report 2014 provides a professional, multidisciplinary assessment of all aspects of the geographical distribution, biology, etiology, prevention, and control of cancer, predicated on research. World Cancer Report is designed to provide non-specialist health professionals and policy-makers with a balanced understanding of cancer control and to provide established cancer professionals with insights about recent developments. |
| dostarlimab fda approval history: Red Book Thomson, 2008 The new 2008 Red Book not only presents the latest pricing and product information on more than 160,000 prescription and over-the-counter items, but also a complete list of newly FDA-approved brands, generics, and biologics. |
Dostarlimab - Wikipedia
Dostarlimab, sold under the brand name Jemperli, is a monoclonal antibody used as an anti-cancer medication for the treatment of endometrial cancer. [ 5 ] [ 6 ] [ 10 ] Dostarlimab is a programmed …
Dostarlimab Uses, Side Effects & Warnings - Drugs.com
Jun 11, 2024 · Dostarlimab is used to treat adults with certain cancers after other treatments did not work or stopped working, and/or the cancer has returned, or it has spread or cannot be removed …
Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer
Mar 27, 2023 · Dostarlimab is an immune-checkpoint inhibitor that targets the programmed cell death 1 receptor. The combination of chemotherapy and immunotherapy may have synergistic …
Dostarlimab: The miracle drug for the treatment of colorectal cancer
Dostarlimab is an antibody to anti-programmed cell death receptor-1 (PD-1) which is used for the treatment of adults with mismatch repair-deficient (dMMR) recurrent or advanced solid tumors …
FDA grants accelerated approval to dostarlimab-gxly for dMMR …
On August 17, 2021, the Food and Drug Administration granted accelerated approval to dostarlimab-gxly (Jemperli, GlaxoSmithKline LLC) for adult patients with mismatch repair …
Dostarlimab-gxly - NCI - National Cancer Institute
Dostarlimab-gxly is a type of drug called an immune checkpoint inhibitor (a type of immunotherapy). It is a monoclonal antibody that binds to the protein PD-1 on the surface of …
EC Treatment Option for Certain Patients | JEMPERLI (dostarlimab …
JEMPERLI is a medicine that may treat certain cancers by working with your immune system. JEMPERLI can cause your immune system to attack normal organs and tissues in any area of …
Dostarlimab-gxly (intravenous route) - Mayo Clinic
Dostarlimab-gxly is a monoclonal antibody that changes the immune system to help control the growth of cancer cells. This medicine is to be given only by or under the direct supervision of …
Dostarlimab (Jemperli®) - Macmillan Cancer Support
Dostarlimab (Jemperli®) is an immunotherapy drug. It may also be called a checkpoint inhibitor. It is best to read this information with our general information about immunotherapy drugs and the …
Jemperli (dostarlimab-gxly) - Uses, Side Effects, and More
Oct 23, 2024 · Jemperli (dostarlimab-gxly) is commonly used to treat certain solid tumor cancers, including endometrial cancer. Jemperli may also be used for other conditions as determined by …
Dostarlimab - Wikipedia
Dostarlimab, sold under the brand name Jemperli, is a monoclonal antibody used as an anti-cancer medication for the treatment of endometrial cancer. [ 5 ] [ 6 ] [ 10 ] Dostarlimab is a programmed …
Dostarlimab Uses, Side Effects & Warnings - Drugs.com
Jun 11, 2024 · Dostarlimab is used to treat adults with certain cancers after other treatments did not work or stopped working, and/or the cancer has returned, or it has spread or cannot be removed …
Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer
Mar 27, 2023 · Dostarlimab is an immune-checkpoint inhibitor that targets the programmed cell death 1 receptor. The combination of chemotherapy and immunotherapy may have synergistic …
Dostarlimab: The miracle drug for the treatment of colorectal cancer
Dostarlimab is an antibody to anti-programmed cell death receptor-1 (PD-1) which is used for the treatment of adults with mismatch repair-deficient (dMMR) recurrent or advanced solid tumors …
FDA grants accelerated approval to dostarlimab-gxly for dMMR …
On August 17, 2021, the Food and Drug Administration granted accelerated approval to dostarlimab-gxly (Jemperli, GlaxoSmithKline LLC) for adult patients with mismatch repair …
Dostarlimab-gxly - NCI - National Cancer Institute
Dostarlimab-gxly is a type of drug called an immune checkpoint inhibitor (a type of immunotherapy). It is a monoclonal antibody that binds to the protein PD-1 on the surface of …
EC Treatment Option for Certain Patients | JEMPERLI (dostarlimab …
JEMPERLI is a medicine that may treat certain cancers by working with your immune system. JEMPERLI can cause your immune system to attack normal organs and tissues in any area of …
Dostarlimab-gxly (intravenous route) - Mayo Clinic
Dostarlimab-gxly is a monoclonal antibody that changes the immune system to help control the growth of cancer cells. This medicine is to be given only by or under the direct supervision of …
Dostarlimab (Jemperli®) - Macmillan Cancer Support
Dostarlimab (Jemperli®) is an immunotherapy drug. It may also be called a checkpoint inhibitor. It is best to read this information with our general information about immunotherapy drugs and the …
Jemperli (dostarlimab-gxly) - Uses, Side Effects, and More
Oct 23, 2024 · Jemperli (dostarlimab-gxly) is commonly used to treat certain solid tumor cancers, including endometrial cancer. Jemperli may also be used for other conditions as determined by …
